at San Francisco, California and other locations
study started
completion around
Principal Investigator
by Charalambos Andreadis



Per Health Authorities guidelines for gene therapy medicinal products that utilize integrating vectors (e.g. lentiviral vectors), long term safety and efficacy follow up of treated patients is required. The purpose of this study is to monitor all patients exposed to CAR-T therapied for 15 years following their last CAR-T (e.g. CTL019) infusion to assess the risk of delayed adverse events (AEs), monitor for replication competent lentivirus (RCL) and assess long-term efficacy, including vector persistence.

Official Title

Long Term Follow-Up of Patients Exposed to Lentiviral-Based CAR T-Cell Therapy


Patients are enrolled following completion or early discontinuation from a Novartis sponsored or supported study of CAR T-Cell treatment. Patients will be followed for 15 years post treatment from the last treatment. They will be monitored for safety and efficacy within the primary treatment protocols for the protocol defined duration. Patients can drop off treatment protocols at any time to enter this long term Follow up study. Patients discontinuing from the primary treatment protocols for any reason will be enrolled in this long term follow up (LTFU). This will allow collecting data on long term safety and efficacy (as applicable) as mandated by the health authorities of all patients treated with CAR-T therapy within the concept of a single protocol.

Collection of such long term effects of CAR-T cell therapy will help to further define the risk-benefit profile of CAR-T Therapies.


Long Term Safety of Patients Receiving CAR-T in an Eligible Clinical Trial or Managed Access Program, Previously treated CAR-T patients


You can join if…

  • All patients who have received a CAR-T therapy and completed or discontinued early from a Novartis sponsored treatment protocol that utilized CAR-T cells or from any CAR-T trial sponsored by the University of Pennsylvania with which Novartis has a contractual agreement to co-develop the CAR technology.
  • Patients who have provided informed consent for the long term follow up study prior to their study participation .

You CAN'T join if...

- There are no specific exclusion criteria for this study.


  • UCSF Medical Center . accepting new patients
    San Francisco California 94143 United States
  • Stanford Universtiy Medical Center SC - CTL019B2205J - B2206 accepting new patients
    Stanford California 94304 United States

Lead Scientist at UCSF


accepting new patients
Start Date
Completion Date
Novartis Pharmaceuticals
Phase 3 CAR T-Cell Therapy Research Study
Study Type
Expecting 1400 study participants
Last Updated